🇺🇸 FDA
Pipeline program

Ozanimod, Ozanimod, Ozanimod

IM047-001

Phase 3 small_molecule active

Quick answer

Ozanimod, Ozanimod, Ozanimod for Moderately to Severely Active Ulcerative Colitis is a Phase 3 program (small_molecule) at Bristol-Myers Squibb / Pfizer EEIG with 1 ClinicalTrials.gov record(s).

Program details

Company
Bristol-Myers Squibb / Pfizer EEIG
Indication
Moderately to Severely Active Ulcerative Colitis
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials